T1	Participants 52 98	patients with pulmonary arterial hypertension.
T2	Participants 172 223	patients with pulmonary arterial hypertension (PAH)
T4	Participants 895 963	98 randomized patients, 61% were WHO functional class II at baseline
T3	Participants 505 522	patients with PAH
